EDAP TMS Toekomstige groei

Future criteriumcontroles 1/6

De verwachting is dat EDAP TMS de winst en omzet met respectievelijk 45.3% en 19.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 47.3% per jaar.

Belangrijke informatie

45.3%

Groei van de winst

47.3%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	19.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	08 Nov 2024

Recente toekomstige groei-updates

Recent updates

Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?

Oct 24

Slammed 35% EDAP TMS S.A. (NASDAQ:EDAP) Screens Well Here But There Might Be A Catch

Sep 07

Fewer Investors Than Expected Jumping On EDAP TMS S.A. (NASDAQ:EDAP)

Jul 24

There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump

Mar 22

EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M

Aug 24

EDAP's Focal One Revenue Is Set To Accelerate

Aug 08

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

Jul 19

Acceleration At EDAP

Jan 11

EDAP TMS (NASDAQ:EDAP) Could Easily Take On More Debt

Jan 06

The Consensus EPS Estimates For EDAP TMS S.A. (NASDAQ:EDAP) Just Fell A Lot

Nov 25

EDAP's HIFU Progress Is Obscured By The Pandemic, But It's Real

Sep 07

EDAP's subsidiary names medTech industry veteran Ryan Rhodes as CEO

Jun 15

EDAP TMS S.A. (NASDAQ:EDAP) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Apr 02

Analysts Are Betting On EDAP TMS S.A. (NASDAQ:EDAP) With A Big Upgrade This Week

Jan 24

Treatment with EDAP's HIFU ultrasound benefits in prostate cancer patients, study shows

Jan 14

New reimbursement rules for HIFU technology to favor EDAP TMS

Dec 09

EDAP TMS S.A. EPS misses by $0.02, beats on revenue

Nov 18

Winst- en omzetgroeiprognoses

NasdaqGM:EDAP - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	84	-14	N/A	N/A	3
12/31/2025	74	-17	N/A	N/A	3
12/31/2024	64	-21	N/A	N/A	3
9/30/2024	63	-22	-23	-19	N/A
6/30/2024	62	-20	-19	-16	N/A
3/31/2024	61	-18	-20	-16	N/A
12/31/2023	60	-21	-19	-15	N/A
9/30/2023	57	-21	-21	-17	N/A
6/30/2023	57	-17	-17	-13	N/A
3/31/2023	57	-11	-10	-7	N/A
12/31/2022	55	-3	-5	-3	N/A
9/30/2022	53	4	4	6	N/A
6/30/2022	51	3	3	5	N/A
3/31/2022	47	0	2	4	N/A
12/31/2021	44	1	3	4	N/A
9/30/2021	45	0	4	6	N/A
6/30/2021	45	0	N/A	N/A	N/A
3/31/2021	44	0	N/A	N/A	N/A
12/31/2020	42	-2	0	2	N/A
9/30/2020	38	-3	N/A	N/A	N/A
6/30/2020	39	-2	N/A	N/A	N/A
3/31/2020	42	0	N/A	N/A	N/A
12/31/2019	45	2	2	4	N/A
9/30/2019	46	4	N/A	N/A	N/A
6/30/2019	44	2	N/A	N/A	N/A
3/31/2019	40	0	N/A	N/A	N/A
12/31/2018	39	0	-2	0	N/A
9/30/2018	36	-1	N/A	N/A	N/A
6/30/2018	35	-1	N/A	0	N/A
3/31/2018	36	-2	N/A	N/A	N/A
12/31/2017	36	-1	N/A	-3	N/A
9/30/2017	36	-2	N/A	N/A	N/A
6/30/2017	37	0	N/A	-4	N/A
3/31/2017	36	4	N/A	N/A	N/A
12/31/2016	36	4	N/A	1	N/A
9/30/2016	37	10	N/A	N/A	N/A
6/30/2016	35	4	N/A	4	N/A
3/31/2016	35	2	N/A	N/A	N/A
12/31/2015	32	-2	N/A	1	N/A
9/30/2015	27	-9	N/A	N/A	N/A
6/30/2015	27	2	N/A	-1	N/A
3/31/2015	25	-4	N/A	N/A	N/A
12/31/2014	26	-1	N/A	-1	N/A
9/30/2014	28	2	N/A	N/A	N/A
6/30/2014	27	-5	N/A	-1	N/A
3/31/2014	26	0	N/A	N/A	N/A
12/31/2013	24	-5	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat EDAP de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat EDAP de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat EDAP de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van EDAP ( 19.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van EDAP ( 19.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van EDAP naar verwachting over 3 jaar hoog zal zijn

EDAP TMS Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 35%, revenue upgraded

Consensus EPS estimates fall by 11%, revenue upgraded

Consensus EPS estimates fall by 199%

Price target increased by 9.1% to US$15.00

Price target increased by 12% to US$14.50

Consensus EPS estimates increase by 36%

Recent updates

EDAP TMS S.A. to Report Q3, 2024 Results on Nov 07, 2024

Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?

EDAP TMS S.A. Announces First Patients Treated in Phase I/Ii Study Evaluating Focal One Robotic Hifu for the Treatment of Benign Prostatic Hyperplasia (Bph)

Slammed 35% EDAP TMS S.A. (NASDAQ:EDAP) Screens Well Here But There Might Be A Catch

EDAP TMS S.A. Announces Resignation of Marc Oczachowski as Chairman of Board of Directors, Effective September 30, 2024

EDAP TMS S.A. to Report Q2, 2024 Results on Aug 28, 2024

Fewer Investors Than Expected Jumping On EDAP TMS S.A. (NASDAQ:EDAP)

EDAP TMS S.A. Announces Interim Results from Phase 3 Study Evaluating Robotic Hifu for the Treatment of Deep Infiltrating Endometriosis

EDAP TMS S.A. Appoints Fran Schulz to Board of Directors

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 35%, revenue upgraded

EDAP TMS S.A. to Report Q1, 2024 Results on May 16, 2024

Consensus EPS estimates fall by 11%, revenue upgraded

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump

EDAP TMS S.A. to Report Q4, 2023 Results on Mar 27, 2024

EDAP TMS SA Announces FDA Breakthrough Device Designation for Focal One in the Treatment of Deep Infiltrating Rectal Endometriosis

Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?

EDAP TMS S.A. Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One Hifu Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis

It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)

EDAP TMS S.A. Appoints Francois Dietsch as Global Chief Accounting Officer

Less than half of directors are independent

EDAP TMS S.A. Announces Board Changes

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

EDAP TMS S.A. to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

EDAP TMS S.A. Announces Board Changes

New major risk - Revenue and earnings growth

EDAP TMS S.A. to Report Q2, 2023 Results on Aug 24, 2023

Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)

Insufficient new directors

EDAP TMS S.A., Annual General Meeting, Jun 30, 2023

Consensus EPS estimates fall by 199%

Price target increased by 9.1% to US$15.00

First quarter 2023 earnings released: €0.20 loss per share (vs €0.011 profit in 1Q 2022)

EDAP TMS S.A. to Report Q1, 2023 Results on May 17, 2023

Price target increased by 12% to US$14.50

Full year 2022 earnings released: €0.085 loss per share (vs €0.022 profit in FY 2021)

Consensus EPS estimates increase by 36%

EDAP TMS SA Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound for the Treatment of Rectal Endometriosis

Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?

Now 20% undervalued

EDAP TMS S.A. Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis

EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals

Consensus EPS estimates have been upgraded

Third quarter 2022 earnings released: EPS: €0 (vs €0.03 loss in 3Q 2021)

Now -35% undervalued

EDAP TMS S.A. to Report Q3, 2022 Results on Nov 16, 2022

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS stock falls 7% aftermarket on proposed ADS offering

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M

EDAP's Focal One Revenue Is Set To Accelerate

EDAP TMS S.A. to Report Q2, 2022 Results on Aug 24, 2022

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

EDAP TMS S.A., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. to Report Q1, 2022 Results on May 17, 2022

EDAP TMS S.A. to Showcase Its Focal One® Platform At the Annual Meeting of the American Urological Association

Price target decreased to US$12.00

Consensus EPS estimates have been downgraded.

Full year 2021 earnings: EPS and revenues miss analyst expectations

EDAP TMS S.A. to Report Q4, 2021 Results on Mar 30, 2022